Japan has approved Bristol-Myers Squibb Co.'s all-oral Daklinza and Sunvepra dual regimen to treat hepatitis C, the company said Monday.

The combined treatment, which is interferon- and ribavirin-free, is a new option for genotype 1 hepatitis C patients in Japan that haven't been able to take or respond to traditional treatments, the drug maker said in a statement. The treatment was approved by the Japanese Ministry of Health, Labor...